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INTRODUCTION         
Systemic sclerosis (SSc) is associated with chronic inflammation, 
fibrosis and obliterative vasculopathy within the skin and visceral 
organs. SSc is an autoimmune disorder characterized by widespread 
vasculopathy. The microvasculature is primarily affected. However, 
large-vessel disease also occurs in SSc [1–6]. Accelerated 
atherosclerosis has been described in some patients with SSc [7]. This 
occurred despite the absence of classical vascular risk factors. 
Macrovascular disease was observed in 58% of patients with limited 
cutaneous SSc (lcSSc) [2, 4].Intermittent claudication, cardiovascular 
disease (CVD) and cerebrovascular disease were detected in 22%, 15% 
and 6.5% of SSc patients, respectively [7]. 
Vascular abnormalities have long been recognized as being 
central to the pathogenesis of SSc, and SSc has been suggested to be 
primarily a vascular disease [8,9]. Both structural and functional 
changes occur, which interrelate [10]. Structural  changes  affect digital 
microcirculation ( well demonstrated with nailfold capillaroscopy)  and  
the  digital arteries, in which the most characteristic  histologic lesion is 
marked intimal hyperplasia/fibrosis [11]. Although involvement of 
peripheral arteries proximal to the digital arteries was previously 
believed to be unusual, in the past  15 years considerable interest has 
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been shown in the hypothesis that patients who have SSc  have an 
increased prevalence of large vessel disease [12-14] 
Endothelial dysfunction is thought to be an important factor in the 
pathogenesis of atherosclerosis. In healthy subjects, endothelium is 
more than a physical barrier and has several functions, like:  
(a) continuous regulation of vascular tone, (b) leucocytes adhesion,  
(c) maintenance of the balance between thrombotic and anticoagulant 
properties of the blood [15]. When these functions of the endothelium 
are affected, endothelial dysfunction appears. Endothelial cell activation 
is an initiating step in atherogenesis [16].  
Endothelial function can be assessed noninvasively by means of 
several methods, based on the inability of dysfunctional endothelium to 
cause vasodilation of the vessels by its inability to release endothelium-
derived vasodilatory mediators. 
Endothelium independent vasodilation can be studied by using 
glyceryl nitrate, causing vasodilation by direct action on the smooth 
muscle [17,18]. Measurement of flow-mediated dilatation (FMD, 
endothelium-dependent) and endothelium-independent vasodilatation via 
high ultrasound techniques allowed the detection of endothelial 
dysfunction in children and adults with risk factors for atherosclerosis 
[17]. A relationship among endothelial dysfunction, IMT (Intima-Medial 
Thickness) and cardiovascular risk factors has been established[19]. 
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Angiography demonstrated rigidity of various arteries [6]. 
Increased intimal-medial thickness of the common carotid artery 
(ccIMT) has been described in 64% of SSc patients [3, 6, 20] Early 
endothelial dysfunction has been described in rheumatoid arthritis (RA) 
and lupus (reviewed in [3, 4]). However, there are very few studies 
assessing flow-mediated (FMD) or nitrate-mediated vasodilatation 
(NMD) in SSc. FMD measured on the brachial artery at rest and during 
reactive hyperaemia indicates endothelium-dependent vasodilatation, 
while NMD assessed after administration of sublingual nitroglycerin, is 
an indicator of endothelium-independent vasodilatation [8, 21]. 
High-frequency ultrasonographic imaging of the brachial artery to 
assess endothelium-dependent flow-mediated vasodilatation (FMD) was 
developed in the 1990’s .The technique provokes the release of nitric 
oxide, resulting in vasodilatation that can be quantitated as an index of 
vasomotor function. The noninvasive nature of the technique allows 
repeated measurements over time to study the effectiveness of various 
interventions that may affect vascular health[22]. 
Very high interest exists in determining  the clinical utility of  
brachial artery FMD. Investigators have hypothesized that endothelial 
function may serve as an integrating index of risk factor burden and 
genetic susceptibility, and that  endothelial dysfunction will prove to be 
a preclinical marker of cardiovascular disease [23]. Several studies 
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suggest that the presence of endothelial dysfunction in the coronary 
circulation is an independent predictor of cardiovascular disease events 
[24,25]. The technique is particularly well suited for study of the earliest 
stages of  atherosclerosis  in children and young adults, thus providing 
maximal opportunity for prevention. Recently, endothelial dysfunction 
has also been found in patients with systemic vasculitis and has been 
reversed by administration of immunosuppressive therapy [26]. As 
endothelial dysfunction may represent an early stage in atherogenesis, it 
is important to understand the mechanisms of its development in a 
condition such as SSc. It is also important to determine whether it is 
associated with other Coronary Heart Disease (CHD) risk factors or 
early atheroma. 
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REVIEW OF LITERATURE 
Systemic sclerosis is a generalized disorder of connective tissue 
[27] characterized clinically by thickening and fibrosis of skin and by 
distinctive form of involvement of internal organs notably the heart, 
lungs, kidney and G.I.T [28]. Morbidity and mortality are substantial 
and are directly related to the extent and severity of visceral 
involvement [27]. Scleroderma or systemic sclerosis is characterized by 
fibrosis and microvascular occlusion. Similar to other autoimmune 
rheumatic diseases, including Systemic Lupus Erythematosis (SLE) and 
Rheumatoid Arthritis (RA), macrovascular disease can occur in SSc, 
although its frequency is unknown. 
Three major types of abnormalities have been described in the 
pathogenesis of the disease. First, there is an impairment of the immune 
system resulting in chronic inflammation, abnormal T cell activation, 
abundant production of proinflammatory cytokines such as interleukin 4, 
B cell dysfunction and the production of characteristic autoantibodies 
including anticentromere antibodies in limited cutaneous SSc (lcSSc) 
and antitopoisomerase 1 and anti-RNA polymerase I/III antibodies in 
diffuse cutaneous SSc (dcSSc) [29,30 ]Second, there is functional 
impairment of the microvasculature including the vascular endothelium, 
contributing to tissue hypoxia [31,32]. Finally, there is a structural 
vasculopathy caused by extracellular matrix deposition into the vessel 
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wall. At the cellular and molecular level, this phenomenon has been 
associated with disproportionate fibroblast activity, as well as increased 
serum levels of hyaluronan, matrix metalloproteinases (MMP) and tissue 
inhibitors of metalloproteinases  (TIMP) [33,34]. Some features of the 
disease resemble the processes taking place in an atherosclerotic plaque 
[35]. 
The etiology of SSc remains elusive despite significant advances 
in the understanding of the pathogenetic mechanisms of the disease 
since its initial description in the medical literature almost 250 years 
ago. SSc can be conceptualized as tripartite disease in which 
dysfunction of the immune system, endothelium and fibroblasts give rise 
to a heterogenous phenotype that is marked by prominent fibrosis. 
Autoimmunity is manifested by the elaboration of circulating 
disease specific autoantibodies [36]. Fibroblast dysfunction is 
manifested as fibrosis of skin and internal organs as the result of 
increased synthesis and deposition of extracellular matrix (ECM) 
proteins [37,38]. Raynaud’s phenomenon, capillary dropout, enthothelial 
injury/ apoptosis and abnormalities in vascular tone are manifestations 
of endothelial dysfunction. 
Genetic factors may play a role in the dysregulation of these 
components by affecting host susceptibility to disease or modifying 
clinical presentation and organ damage. Available data are consistent 
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with the paradigm that the phenotype identified as SSc is the end result 
of a complex interaction of genetic factors and unknown environmental 
influences. 
The pathologic hallmark of systemic sclerosis is an excessive 
accumulation of ECM in the dermis, which leads to taut skin. In the 
early stages of SSc, an infiltration of mononuclear inflammatory cells, 
predominantly T cells [39], surrounding the dermal blood vessels is 
concentrated at the border between the reticular dermis and 
subcutaneous fat. There is intimal proliferation with luminal narrowing 
at the arterial and arteriolar levels. Capillary loss can be seen in vivo in 
the skin by widefield nailfold capillaroscopy. 
Pathogenic factors involved in SSc-associated vascular damage 
include increased low density lipoprotein (LDL), homocysteine and C 
reactive protein (CRP) production [3, 31, 32]. 
Neudecker et al have recently described the association of 5,10-
methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism 
with homocysteine, vitamin B12 production and macrovascular 
abnormalities in SSc [33]. They also detected increased serum adhesion 
molecule levels in SSc patients with macrovascular disease [34]. 
Atherosclerosis is considered to be a chronic inflammatory 
disorder. Several autoimmune rheumatic diseases are characterized by 
premature and accelerated atherosclerosis in which both classical and 
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non-classical risk factors contribute to atherogenesis. In SSc patients 
admitted to the hospital because of acute myocardial infarction, the odds 
ratio of having normal coronary arteries was 33.89 compared with the 
patients admitted from the general population, suggesting microvascular 
and not macrovascular disease in these patients [40] 
Also, cerebrovascular involvement in SSc has rarely been 
documented, although the opposite has been stated [41]. Only one 
retrospective cohort study is available, showing no increased prevalence 
of cerebrovascular disease in 31 female SSc patients compared with 
matched controls (prevalence 26 vs 19%, RR 1.3 with 95% CI of 0.5, 
3.3) [42]. 
An increased prevalence of peripheral vascular disease in SSc 
patients compared with healthy controls (21.7 vs 4.6%) has been 
observed by Veale et al. [43], using a questionnaire for intermittent 
claudication, and by Youssef et al. [42], using data available from 
angiography, Doppler ultrasound or physical examination (prevalence 
58 vs 10%, RR 6.0 with 95% CI of 2.0, 18). When angiographic findings 
of the lower and upper limb in SSc patients were related to 
cardiovascular risk factors, an association was observed between these 
risk factors and proximal peripheral artery disease, but not distal 
peripheral artery disease [44]. Distal peripheral artery disease is present 
in the digits of many SSc patients, showing a high frequency of digital 
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stenosis and occlusions in the digital arteries of patients. Lesions were 
most frequently found in the 2nd to 5th palmar digital artery, the ulnar 
artery and the superficial palmar arch [45-48]. As a consequence, digital 
ischaemia, ulceration or amputation is a well-known, but feared 
manifestation in SSc [49-51]. 
An increased prevalence of distal peripheral artery disease in the 
digits has been found. The prevalence of coronary artery disease and 
cerebrovascular disease is not increased, although studies using intima–
media thickness of the carotid artery as a marker of early atherosclerosis 
showed discrepant results. Besides traditional risk factors, as present in 
the general population, non-traditional risk factors are present in SSc as 
well, such as increased lipoprotein (a), oxidized LDL, inflammation, 
vasospasm and endothelial dysfunction. Moreover, markers of vascular 
damage in atherosclerosis, like antibodies to oxidized LDL, and 
increased levels of soluble vascular adhesion molecules, have been 
described in association with vascular damage in SSc. Nevertheless, 
generalized premature atherosclerosis has not been detected in SSc. 
Therefore, further research is necessary to assess the prevalence of 
clinically manifest or subclinical early atherosclerosis in SSc. 
In ulnar artery biopsies, intimal thickening and transmural 
lymphocytic infiltrates were detected without the presence of 
atherosclerotic plaques [6]. Microvascular abnormalities and Raynaud’s 
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Phenomenon (RP) are well-known as major sites of pathology [52-55], 
but less attention has been paid to macrovascular abnormalities.   The 
prevalence of vascular abnormalities in SSc has been considered to be 
inversely proportional to the size of blood vessels studied [56]. 
Macrovascular disease was considered extremely rare. 
There have been several reports that macrovascular disease is 
increased in SSc. Taken together, these studies provide evidence that 
there is increased macrovascular pathology, with severalfold greater risk 
of symptomatic disease and possibly also increased asymptomatic 
disease. Important questions remain unanswered though, especially 
whether it relates directly to SSc or whether it reflects other genetic or 
environmental characteristics of the scleroderma population.Factors 
related to the vasospastic or fibrotic pathologies of SSc might be 
involved in the development of co-existing macrovascular disease. 
Large vessel involvement has important implications for organ-
based complications, such as renal disease, peripheral ischemia and 
bowel involvement. Noninvasive studies have shown blood flow 
abnormalities in the large vessels in the cerebral and renal circulation in 
patients with SSc [57] and symptomatic and asymptomatic macrovascular 
disease are increased [58,59]. A more recent study of macrovascular 
involvement showed a predilection for the ulnar artery [60]. Postmortem 
studies have reported that cerebrovascular disease, especially with 
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vascular calcification, may be disproportionately severe in patients with 
lcSSc compared with macrovascular disease at other sites [59a]. 
Although a mild vasculitis may sometimes be present, the 
vascular pathology of SSc is not necessarily inflammatory and is best 
characterized as a vasculopathy.  Arterial occlusion in SSc is common, 
particularly in the ulnar arteries in patients with the lcSSc and in 
association with anticentromere antibodies [70].   
 Studies investigating the prevalence of lower limb large vessel 
disease have shown conflicting results. Veale and colleagues [61] 
reported that 10 of 46 patients (21.7%) who had SSc who participated in 
a questionnaire - based study experienced claudication, compared with 
4.5% of the population of a neighboring region in Scotland. The same 
investigators then reported ankle-brachial pressure indices (ABPI) of 
less than 0.9 in 9 of 53 patients who had SSc (17%) but in none of 43 
controls, with 21 (40%) patients who had SSc having an ABPI of less 
than 1 compared with 4 (10%) controls [62]. However a later study of 
119 patients who had SSc reported that only 12% had an ABPI of less 
than 1.0, but this study didn’t include a control group [63]. A recent 
study found no differences in ABPIs between 53 patients who had SSc 
and 43 controls, despite higher intima-media thickness (an index of 
atherosclerotic carotid artery disease) in the SSc group [64].  
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If macrovascular disease is increased in SSc, it may be from the 
SSc disease process or because of an increased prevalence of 
atheromatous disease as reported in other rheumatic diseases. Despite 
whether the prevalence of large vessel peripheral arterial disease is 
increased in SSc, atheromatous disease is common , especially in older 
patients, and the coexistence of proximal and small vessel disease in 
SSc  is potentially limb threatening. It is important not to miss, for 
example, a subclavian or superficial femoral artery stenosis that may be 
amenable to angioplasty or surgery. 
Upper and lower limb arteriographic studies in patients who have 
SSc, mostly with critical digital ischemia, have shown a combination of 
proximal and digital arterial disease, although in small numbers of 
patients. Hasegawa and colleagues [65] described arteriographic 
findings in 8 patients who had SSc and severe digital ischemia; 7 had 
digital artery occlusions, but 4 also  had  arterial occlusions proximal to 
the digits and in 3, the ulnar artery was involved .These authors 
reviewed the earlier literature on arteriographic findings in SSc [65]. 
Three previous groups of investigators reported ulnar artery occlusion 
on angiography in patients who had SSc:  in 11 of 31 patients [66], 10 of 
24 has (12 patients) [67] and 9 of 29 patients [68]. In contrast, radial 
artery involvement was only rarely reported. Ulnar artery disease was 
also reported in a retrospective study by Stafford and colleagues [69], 
who found that 10 of 19 patients who had SSc who had ulnar arterial 
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wall abnormalities on Doppler ultra sound, and by Tailor and colleagues 
[70], who reported ulnar artery involvement in all 15 patients (9 had 
bilateral involvement) who underwent arteriography based on severe 
digital ischemia / ulceration and a positive Allen’s test (all 15 patients 
also had digital artery disease). Why the ulnar artery should be involved 
more than the radial artery is unknown? 
Avascular necrosis (AVN) is caused by death of the bone, likely 
caused by interrupted circulation to the marrow and trabeculae [71]. It 
rarely can occur in scleroderma, probably secondary to both macro and 
microvacsular abnormalities that are part of the underlying disease 
process [72]. Initial case reports of bilateral hip[73] and bilateral ankle 
[73] ischemic necrosis in SSc  were notable in the disease of significant 
corticosteroid therapy, arthropathy, vasculitis or anticardiolipin (Acl) 
antibodies.Fewer reports describe osteonecrosis of the wrist in SSc. One 
report of AVN of the carpal scaphoid was in a patient treated with 25 
gm of prednisone over 8 yrs [74]. Another subject who suffered bilateral 
lunate osteonecrosis had severe Raynaud’s Phenomenon and vasculitis 
[75]. In the author’s centre, 3 patients, two of whom had no 
corticosteroid exposure, developed osteonecrosis of the lunate [76]. It is 
important to recognize AVN early, because revascularization of the 
involved bone may be prevent bone death. 
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LIPOPROTEIN PROFILE 
Decreased HDL levels have been detected in patients with limited 
cutaneous SSc (lcSSc) compared with healthy controls [77]. No studies 
are available on LDL levels in SSc. However, patients with SSc showed 
increased susceptibility to oxidation of LDL, a process in which 
oxidized LDL (OxLDL) is formed [78]. OxLDL is a proatherogenic 
lipoprotein, which, amongst others, promotes foam cell formation, 
vascular oxygen radical formation, tissue remodelling, endothelial 
dysfunction and even vasospasm [79, 80]. Another cardiovascular 
pathogenic factor is lipoprotein(a) [Lp (a)] [81]. Its exact mechanism is 
unknown, but Lp (a) counterbalances the pro- and anti-coagulant, pro- 
and anti-inflammatory and vasorelaxing and vasoconstricting properties 
of the endothelium, in which raised concentrations are linked with 
atherosclerosis and thrombosis [82, 83]. In patients with SSc, increased 
concentrations of Lp (a) without further differences in lipid profile in 
comparison with healthy controls have been found, both in lcSSc and 
dcSSc [84, 85]. 
INFLAMMATION 
Inflammation is a hallmark of systemic autoimmune diseases. 
Also in SSc, inflammation is present when the disease is active. Disease 
activity in SSc can be assessed by using the preliminary European 
Scleroderma Study Group (EScSG) activity indices (a score ranging 
from 0 to 10). A score of >3 denotes active disease [86, 87]. One of the 
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items of this scale is CRP, found to be a strong marker of cardiovascular 
risk in asymptomatic subjects and subjects with a history of a 
cardiovascular event [88-93]. Elevated acute-phase reactants have been 
found especially in dcSSc (41.8%) compared with lcSSc (24.6%), as 
have been described in the large EULAR Scleroderma Trials and 
Research (EUSTAR) group database [94]. Therefore, inflammation 
might play a role in vascular abnormalities in SSc. No data are available 
concerning acute-phase reactants and atherosclerosis in SSc. 
Large vessel involvement has been suggested in SSc since altered 
elastic properties of the carotid artery, increased stiffness of the aorta 
and decreased arterial distensibility have all been reported in SSc 
patients [95, 96-101].  
The capacity of blood vessels to respond to physical and chemical 
stimuli in the lumen confers the ability to self-regulate tone and to 
adjust blood flow and distribution in response to changes in the local 
environment. Many blood vessels respond to an increase in flow or more 
precisely shear stress, by dilating. This phenomenon is designated FMD. 
A principal mediator of FMD is endothelium-derived NO. The precise 
mechanisms for the acute detection of shear forces and subsequent 
signal transduction to modulate vasomotor tone are not fully understood. 
The endothelial cell membrane  contains specialized ion channels, such 
as calcium-activated potassium channels, that open in response to shear 
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stress[102,103and104].The  effect of potassium channel opening is to 
hyperpolarize the endothelial cell, increasing the driving force for 
calcium entry (there are no votage-gated calcium channels in endothelial 
cells). Calcium activates an enzyme, endothelial nitric oxide synthase 
(eNOS) and the subsequent generation of NO appears to account for 
FMD [105,106].  Indeed, endothelial denudation or treatment with a 
nitric oxide synthase (NOS) inhibitor abolishes FMD in a variety of 
arterial vessels. However, it was recently shown that blood vessels from 
mice genetically engineered to lack the eNOS enzyme (eNOS knockout 
mice) still respond to shear stress by dilating. In the eNOS knockout 
mice, FMD seems to be mediated by endothelium-derived prostanoids, 
as it is blocked by indomethacin [107]. Thus, there is some redundancy 
in the system, and more than one endothelial mediator is capable of 
acting as the signal between endothelium and smooth muscle. It is 
unknown whether other mediators, such as the putative  endothelium-
derived  hyperpolarizing factor, can cause FMD if both NO and 
prostanoids are deficient. 
Several mechanisms may underlie the increase in NO in response 
to changes in shear stress. Very acute changes may be mediated by the 
increase in intracellular calcium that occurs when ion channels open 
(see the previous text). Over slightly longer time periods (minutes), 
shear-stress-induced phosphorylation of eNOS via a serine/threonine 
protein kinase, Akt/PKB, increases eNOS activity, even at low calcium 
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concentrations, and this may be important to allow continued output of 
NO [108,109].  In addition, other posttranslational modifications of the 
enzyme (myristilation or palmitoylation) or interaction with caveolin 
can affect intracellular localization of the enzyme and thereby alter its 
function. Over longer time periods (many minutes or hours), eNOS gene 
transcription is activated, and this can result in continued increases in 
NO generation if shear stress is maintained at high levels. 
ENDOTHELIAL DYSFUNCTION 
Endothelial cell activation is an initiating step in atherogenesis 
[110]. Endothelial function can be assessed noninvasively by means of 
several methods, based on the inability of dysfunctional endothelium to 
cause vasodilation of the vessels by its inability to release endothelium-
derived vasodilatory mediators.  
To  assess  endothelial function noninvasively, brachial arteries 
are scanned with high resolution ultrasound imaging, under baseline  
conditions  (at rest) and during hyperemia induced by inflation and 
deflation of a sphygmomanometer cuff  mostly around the forearm distal 
to the site to be scanned with ultrasound. The induced shear stress 
caused by the increased blood flow following transient ischemia induces 
nitric oxide (NO) release, which in turn causes local arterial 
vasodilatation. Endothelial function, defined as flow mediated dilatation 
(FMD), is estimated as the percentage increase in vessel diameter from 
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baseline conditions to maximum vessel diameter during hyperemia. 
Impaired endothelial function of the brachial artery assessed in this  
manner  has been reported in asymptomatic children and adults with 
elevated  cardiovascular risk factors such as smoking [111], 
hypercholesterolemia[112], hypertension [113], diabetes mellitus [114], 
and hyperhomocysteinaemia [115]. Although the results of these studies 
are likely to be internally valid, comparison of the FMD values across 
studies is troublesome.FMD values vary considerably across 
populations, ranging from – 1.9 to 19.2%. 
 Endothelium independent vasodilation can be studied by using 
glyceryl nitrate, causing vasodilation by direct action on the smooth 
muscle [116,117]. Measurement of flow-mediated dilatation (FMD, 
endothelium-dependent) and endothelium-independent vasodilatation via 
high ultrasound techniques allowed the detection of endothelial 
dysfunction in children and adults with risk factors for atherosclerosis 
[116]. A relationship among endothelial dysfunction, IMT and 
cardiovascular risk factors has been established[118]. 
Interestingly, an association between impairments of FMD and 
increased IMT was found in some [119,120] but not all studies [121].     
Several groups have studied subclinical, early atherosclerosis in SSc. 
Using IMT of the carotid artery as a marker of early atherosclerosis 
discrepant results were reported. No differences in IMT or intraluminal 
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diameter of the common carotid artery (CCA) between SSc patients and 
controls were noted by some authors [95,122-124], while others found 
significantly increased IMT values or increased prevalence of carotid 
artery disease in SSc patients (Table 1) [125-129]. IMT values of the 
femoral artery in SSc patients and healthy controls were comparable 
[95,130].   
Treatment with immunosuppressive agents, especially 
corticosteroids, influences the atherogenic process. Corticosteroids are 
considered to have atherogenic properties, [131] like azathioprine, [132] 
whereas for hydroxychloroquine [131] and methotrexate [133] a 
protective effect against atherosclerosis has been described.  
Recently, endothelial dysfunction has also been found in patients 
with systemic vasculitis and has been reversed by administration of 
immunosuppressive therapy [26]. 
An important goal is to extend these preliminary studies and to 
determine whether any of the therapies currently used for Raynaud’s and 
scleroderma might influence development of macrovascular disease. 
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GUIDELINES FOR THE ULTRASOUND ASSESSMENT OF 
ENDOTHELIAL-DEPENDENT FLOW-MEDIATED VASODILATION 
OF THE BRACHIAL ARTERY. A REPORT OF THE 
INTERNATIONAL BRACHIAL ARTERY REACTIVITY TASK 
FORCE MARY C. CORRETTI MD, FACC ET AL 
SUBJECT PREPARATION 
Numerous factors affect flow-mediated vascular reactivity, 
including temperature, food, drugs and sympathetic stimuli, among 
others. Therefore, subjects should fast for at least 8 to 12 h before the 
study, and they should be studied in a quiet, temperature-controlled 
room. All vasoactive medications should be withheld for at least four 
half-lives, if possible. In addition, subjects should not exercise, should 
not ingest substances that might affect FMD such as caffeine, high-fat 
foods and vitamin C or use tobacco for at least 4 to 6 h before the study. 
EQUIPMENT 
Ultrasound systems must be equipped with vascular software for 
two-dimensional (2D) imaging, color and spectral Doppler and a high-
frequency vascular transducer. A linear array transducer with a 
minimum frequency of 7 MHz, attached to a high-quality mainframe 
ultrasound system, is used to acquire images with sufficient resolution 
for subsequent analysis. Image resolution is enhanced with broadband 
(multiple-frequency: 7 to 12 MHz) linear array transducers. 
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IMAGE ACQUISITION 
The subject is positioned supine with the arm in a comfortable 
position for imaging the brachial artery. The brachial artery is imaged 
above the antecubital fossa in the longitudinal plane. A segment with 
clear anterior and posterior intimal interfaces between the lumen and 
vessel wall is selected for continuous 2D grayscale imaging. 
ENDOTHELIUM-DEPENDENT FMD 
To create a flow stimulus in the brachial artery, a 
sphygmomanometric (blood pressure) cuff is first placed either above 
the antecubital fossa or on the forearm. A baseline rest image is 
acquired, and blood flow is estimated by time-averaging the pulsed 
Doppler velocity signal obtained from a midartery sample volume. 
Thereafter, arterial occlusion is created by cuff inflation to suprasystolic 
pressure. Typically, the cuff is inflated to at least 50 mm Hg above 
systolic pressure to occlude arterial inflow for a standardized length of 
time. This causes ischemia and consequent dilation of downstream 
resistance vessels via autoregulatory mechanisms. Subsequent cuff 
deflation induces a brief high-flow state through the brachial artery 
(reactive hyperemia) to accommodate the dilated resistance vessels. The 
resulting increase in shear stress causes the brachial artery to dilate. The  
image of the artery is recorded continuously from 30 s before to 2 min 
after cuff deflation. 
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Studies have variably used either upper arm or forearm cuff 
occlusion, and there is no consensus as to which technique provides 
more accurate or precise information. When the cuff is placed on the 
upper part of the arm, reactive hyperemia typically elicits a greater 
percent change in diameter compared with that produced by the 
placement of the cuff on the forearm [134-136]. This may be due to a 
greater flow stimulus resulting from recruitment of more resistance 
vessels or possibly to direct effects of ischemia on the brachial artery. 
However, upper-arm occlusion is technically more challenging for 
accurate data acquisition as the image is distorted by collapse of the 
brachial artery and shift in soft tissue. The change in brachial artery 
diameter after cuff release increases as the duration of cuff inflation 
increases from 30 s to 5 min. The change in diameter is similar after 5 
and 10 min of occlusion; therefore, the more easily tolerated 5 min 
occlusion is typically used. Also, FMD may be studied in the radial, 
axillary and superficial femoral arteries. Notable caveats are that 
arteries smaller than 2.5 mm in diameter are difficult to measure, and 
vasodilation is generally less difficult to perceive in vessels larger than 
5.0 mm in diameter [137-139]. 
ENDOTHELIUM-INDEPENDENT VASODILATION WITH 
NITROGLYCERIN 
At least 10 min of rest is needed after reactive hyperemia (i.e., 
FMD) before another image is acquired to reflect the reestablished 
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baseline conditions. In most studies to date, an exogenous NO donor, 
such as a single high dose (0.4 mg) of nitroglycerin (NTG) spray or 
sublingual tablet has been given to determine the maximum obtainable 
vasodilator response, and to serve as a measure of endothelium-
independent vasodilation reflecting vascular smooth muscle function. 
Peak vasodilation occurs 3 to 4 min after NTG administration; images 
should be continuously recorded during this time, and NTG should not 
be administered to individuals with clinically significant bradycardia or 
hypotension. Determining the vasodilator responses to increasing doses 
of NTG, rather than a single dose, may further elucidate changes in 
smooth muscle function or arterial compliance that might be playing a 
role in any observed changes in FMD. 
ANATOMIC LANDMARKS 
The diameter of the brachial artery should be measured from 
longitudinal images in which the lumen-intima interface is visualized on 
the near (anterior) and far (posterior) walls. These boundaries are best 
visualized when the angle of insonation is perpendicular. Thus, clear 
visualization of both the near and far wall lumen-intima boundaries 
indicates that the imaging plane is bisecting the vessel in the 
longitudinal direction, and diameters measured from these images likely 
reflect the true diameter. Once the image for analysis is chosen, the 
boundaries for diameter measurements (the lumen-intima or the media-
adventitia interfaces) are identified manually with electronic calipers or 
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automatically using edge-detection software. The variability of the 
diameter measurement is greatest when it is determined from a point-to-
point measurement of a single frame, and least when there is an average 
derived from multiple diameter measurements determined along a 
segment of the vessel. 
The diameter measurement along a longitudinal segment of vessel 
is dependent upon the alignment of the image. Skew occurs when the 
artery is not completely bisected by the plane of the ultrasound beam. 
Some edge-detection programs can account for skew from transducer 
angulation. 
TIMING OF FMD 
Flow-mediated vasodilation is an endothelium-dependent process 
that reflects the relaxation of a conduit artery when exposed to increased 
shear stress. Increased flow, and thereby increased shear stress, through 
the brachial artery occurs during postocclusive reactive hyperemia. 
Several studies have suggested that the maximal increase in diameter 
occurs approximately 60 s after release of the occlusive cuff, or 45 to 60 
s after peak reactive hyperemic blood flow [142,139]. The increase in 
diameter at this time is prevented by the NOS inhibitor NG-
monomethyl-arginine, indicating that it is an endothelium-dependent 
process mediated by No [143,144]. Other measures of vasodilator 
 25
response include time to maximum response [145], duration of the 
vasodilator response [146] and the area under the dilation curve.  
CHARACTERIZING FMD 
Flow-mediated vasodilation is typically expressed as the change 
in post-stimulus diameter as a percentage of the baseline diameter. 
EVALUATING PRECISION OF THE TECHNIQUE 
Intraobserver and interobserver variability in image acquisition 
and analysis should be established and periodically reassessed for each 
condition, including baseline, reactive hyperemia and NTG 
administration. Image variability is best judged by having two 
sonographers independently scan the same series of subjects at different 
times. The highest reproducibility is likely to be shown over a short 
interval, during which the individual vasodilator response is unlikely to 
have changed owing to environmental or other influences. This can be 
accomplished by taking two measurements on the same day within a 10- 
to 15-min interval, or on separate days in otherwise identical 
circumstances. Longitudinal studies in which interventions over weeks 
to months are tested require that reproducibility measurements be 
performed at longer intervals. The image analysis and measurement of 
the vasodilator response from repeated studies should be performed by 
an individual who is blinded as to sequence. Measurement variability is 
assessed, typically, by a designated core laboratory for multicenter 
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trials, prior to site certification and periodically thereafter to analyze for 
temporal drifts.   
Assessment of FMD of the brachial artery in clinical trials has 
increased because of its seeming ease of use, efficiency and noninvasive 
nature. Owing to the biological and technical variability of the 
measurement, several caveats should be considered when planning a 
clinical trial where FMD is the end point of interest. These include study 
design, sample size and uniform technique. 
 
STUDY DESIGN 
Recent studies have reported on the effect of pharmacologic or 
physiologic interventions on FMD of the brachial artery. These include 
both acute [149-151] and longer-term intervention trials [152-154]. Both 
parallel-group and crossover designs have been successfully employed.  
SAMPLE SIZE 
Typically, significant improvement in FMD can be seen with 
20 to 30 patients in a crossover design study and 40 to 60 patients 
in a parallel-group design study. In studies of this size, the 
minimal statistically significant improvement that can be detected 
with intervention is an absolute change in FMD of 1.5% to 2%. 
The sample size depends greatly on the variance of repeated 
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measurement in the control group in a particular vascular 
laboratory. 
With intervention trials, an important parameter to report is 
the time-dependent reproducibility of FMD. For example, in the 
placebo group, the pretreatment and postintervention FMD 
measures are usually reported, and often are very similar. 
However, if the mean difference between the two measurements 
for each patient is quite high, it indicates that the variance of the 
technique might limit interpretation of the study results. An 
acceptable reproducibility is a mean difference of 2% to 3% in 
FMD over time (on a baseline vasodilation of about 10%) [137]. 
This value has not been readily available in published trials. 
METHODOLOGY 
As discussed above, several techniques have been employed 
to measure FMD. Laboratories should select the method that gives 
them the most reproducible results, and for multicenter studies, 
the same scanning protocol should be employed at all  sites.For 
studies employing repeated measurements following intervention, 
FMD might change as a result of the intervention. However, FMD 
could also be affected by a change in the hyperemic stimulus. 
Therefore, the flow stimulus should be consistent. Otherwise, any 
change in FMD of the conduit artery may be related to changes in 
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flow (indirectly mediated by changes in the microcirculation) 
rather than improvement of endothelial function of the conduit 
vessel per se. 
Ultrasound assessment of brachial artery FMD has yielded 
important information about vascular function in health and 
disease, yet several new approaches and technological advances 
have emerged. Most prior studies examined FMD at a single time 
point, typically 1 min after cuff release. This practice evolved 
from the observations that the maximal dilator response occurs at 
approximately 1 min in healthy subjects and that the necessity for 
manual acquisition and measurement placed a practical limit on 
the number of image frames that could be analyzed. 
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AIM 
1) To evaluate macrovascular involvement in SSc  with high 
resolution ultra sonogram (HR-USG) by using the measures of   
a. Flow-mediated  dilatation (FMD), nitroglycerine mediated 
dilatation of the brachial artery  and 
b. Carotid intima-media thickness (ccIMT) . 
2) To  find out any correlation between FMD, NMD, ccIMT and SSc 
disease activity and  clinical characteristics. 
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MATERIALS AND METHODS 
SUBJECTS: 
Patients attending outpatient department and inpatients of 
Department of Rheumatology, Rajiv Gandhi Government General 
Hospital, Chennai were recruited during the period from October 2008 
to March 2011. 32 eligible cases older than 16 years of age were 
enrolled. They fulfilled ACR criteria for SSc and were willing to 
undergo measurement of FMD, NMD and ccIMT. 
Controls were the healthy relatives of the cases who were age and 
sex matched. 
All subjects gave written informed consent to take part in this 
study, which was approved by the ethical committee. 
INCLUSION CRITERIA 
ACR Systemic Sclerosis: Preliminary Classification Criteria 
; Major criteria or two minor criteria for diagnosis 
; Major criterion: Proximal Scleroderma 
; Minor Criteria 
o Sclerodactyly 
o Digital pitting scars or loss of substance from finger pad 
o Bibasilar pulmonary fibrosis 
(Subcommittee for Scleroderma Criteria of the American Rheumatism Association 
Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of 
systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590) 
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EXCLUSION CRITERIA  
1. Overlap syndrome  
2. Mixed Connective Tissue Disease (MCTD ) 
3. Unclassified Connective Tissue Disease (UCTD) 
4. Malignancy 
5. Systemic hypertension       
6. Diabetes mellitus        
7. Smoking 
8. Alcoholism 
 
CLINICAL AND LAB ASSESSMENT 
Detailed history, physical examination and evaluation were done 
in all cases (Photo-A). Laboratory evaluations included complete blood 
count, ESR (Westergren’s method), liver function tests, renal function 
tests, blood sugar and fasting lipid profile. Immunlological assays were 
CRP (Latex agglutination method), ANA (ELISA / HEP2) and ENA 
profile. 
Other investigations included ECG, X-ray Chest PA, USG 
abdomen, Echo-cardiogram and HRCT lungs. Barium swallow and meal 
studies and vascular imaging were also done.  
The extent and severity of skin tightening was recorded with 
Modified Rodnan Skin Scoring System (MRSSS). To assess disease 
activity the preliminary European Scleroderma Study Group (EscSG) 
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activity indices (a score ranging from 0-10) was used. A score higher 
than 3 denotes active disease. (Appendix-I) Also, the revised preliminary SSc 
severity scale (Medsger’s severity scale-Appendix-II), a measure of 
activity, damage and severity, was used. This scale is a 9-organ disease 
severity scale in which for each organ system a score of 0 to 4 is 
applied, with 0 being normal and 4 denoting end stage organ 
involvement. 
ASSESSMENT OF ENDOTHELIAL FUNCTION 
Endothelial function was assessed with high-resolution B-mode 
Doppler (ESAOTE S.P, A-Italia, EIZO NANAO Corporation, Canada 
with a 7-12 MHz linear array transducer) (Photo-B) examination of the 
brachial artery using the protocol described as in the guidelines cited 
previously. Radiologist converse with the techniques of vascular 
imaging assessed flow-mediated dilation (FMD) in response to reactive 
hyperemia. All the subjects were studied between 8 and 11am after a 12-
hour overnight fast. The brachial artery was scanned 10 cm above the 
antecubital fossa (Photo-C). Distance measured was from anterior to 
posterior M lines (media-adventitia interface), and every measurement 
was taken by sonologist blinded to cases and controls. Then, ischemia 
was induced by inflating the pneumatic cuff of sphygmomanometer to a 
pressure 50 mmHg above systolic one, in order to obliterate the brachial 
artery. After 5 minutes, the cuff was deflated and the diameter was 
measured after 60 seconds postdeflation (Df) (Photo-D). 
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FMD is calculated as follows:  
 Post Deflation diameter- resting diameter 
100% x  ----------------------------------------------- 
   Resting Diameter 
ASSESSMENT OF ENDOTHELIUM-INDEPENDENT 
VASODILATION WITH NITROGLYCERIN 
After 20 minutes of taking FMD measurement, 0.4 mg of 
nitroglycerine (NTG) is sprayed sublingually. After 5 minutes of 
sublingual NTG, the diameter of the brachial artery is taken as 
mentioned above (Photo-E). 
NMD is calculated as follows  
 Post NTG diameter – Resting Diameter 
100% x  ----------------------------------------------- 
   Resting Diameter 
CAROTID ARTERY INTIMA-MEDIA THICKNESS AND PLAQUE 
Cases and control subjects also had the intima-media thickness 
(IMT) of their carotid artery measured using high-resolution B-mode 
Doppler (ESAOTE S.P, A-Italia, EIZO NANAO Corporation, Canada 
with a 7-12 MHz – linear array transducer). The common carotid artery 
was scanned longitudinally and the IMT measurement was taken in the 
proximal part of the common carotid artery, 1cm proximal to the carotid 
bulb as the maximum distance between the intima- lumen and 
adventitia-media interfaces. IMT was determined as the average of 6 
measurements, 3 each from the left and right common carotid arteries. 
(Photo-F)  
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To assess reproducibility of our technique, we looked at the 
reliability of reading scans on 2 separate occasions by a single blinded 
observer. For this 10 scans from cases or control subjects were chosen at 
random and baseline diameter, FMD, NMD and ccIMT were measured. 
STATISTICAL ANALYSIS: 
The statistical analysis was performed using the SPSS (version 11.5). 
Results are presented as mean SD, except for frequencies, which 
are expressed as percentages. 
Unpaired student’s t- test has been used for comparing the FMD, 
NMD, ccIMT  and other  features of the study and control group. 
P (less than) 0.05 was considered statistically significant. 
Pearson’s test has been used for studying the correlation between 
FMD and variables. 
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RESULTS 
Total number of cases were 32. The mean age was 36 years. The 
range was from 19-60 years. Majority of them were females – 24(75%). 
Female: Male ratio is 3:1.  
AGE DISTRIBUTION 
Age (Years) Frequency (n) Percent (%) 
< 20 3 9.4 
21 - 30 7 21.9 
31 - 40 11 34.4 
41 - 50 9 28.1 
> 50 2 6.3 
Total 32 100 
 
AGE DISTRIBUTION (%)
9.4
21.9
34.4
28.1
6.3
< 20 21 - 30 31 - 40 41 - 50 > 50
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SEX DISTRIBUTION 
Sex Frequency (n) Percent (%) 
Male 8 25 
Female 24 75 
Total 32 100 
 
 
CLINICAL CHARACTERISTICS OF CASES: 
Limited cutaneous disease was observed in 26 (81%). Diffuse 
cutaneous disease was observed in 6 (19%). Raynaud’s Phenomenon 
was observed in 21 (91%). Digital pitting scar was observed in 17 
(53%). Finger contractures were noted in 11 (34%). Poly Arthralgia was 
noted in 9 (28%). Digital tip ulcerations was noted in 6 (19%).  
Pulmonary involvement was noted in 23 (72%). ILD was seen in 
23 (72%), ILD with traction bronchiectasis was seen in 2 (6%), ILD 
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with emphysematous changes was seen in 2 (6%) and ILD with 
pulmonary hypertension was seen in 2 (6%). 
Cardiac involvement was noted in 6 (19%). ECG changes (ST 
segment/ T wave changes, ventricular premature beats and intra-
ventricular conduction disturbances) was seen in 4 (12%.5), decreased 
LVEF by Echo was seen in 4 (12.5%). 
Gastro Intestinal involvement was noted in 14 (44%), Esophageal 
dysmotility was seen in 14 (44%), Small bowel dysmotility was seen in 
2 (6%). 
Carpal tunnel syndrome was observed in 3 (9%). Sensory 
neuropathy was noted in 3 (9%), Vasculitic Neuropathy was seen in 
1(3%). 
Osteonecrosis of both tibiae and calcaneum was noted in 1 (3%). 
Non nephrotic macro-albuminuria was observed in 1 (3%). 
The duration of disease varied from 6 months to 17 years . Mean 
duration of disease was 3.96 years.  
28 cases (87.5%) were ANA positive. 4 cases (12.5%) were ANA 
negative. 
15 cases were on pulse cyclophosphamide, 5 were on azathioprine 
and 2 each were on azathioprine and methotrexate. 
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CORRELATIONS BETWEEN FMD, NMD, IMT AND OTHER 
PARAMETERS IN CASES 
Parameters   FMD NMD ccIMT
FMD 
r- Value - 0.370 -0.085
P - Value - 0.037* 0.642 
NMD 
r- Value 0.370 - -0.024
P - Value 0.037* - 0.896 
ccIMT 
r- Value -0.085 -0.024 - 
P - Value 0.642 0.896 - 
Age 
r- Value 0.105 -0.109 0.601 
P - Value 0.566 0.552 0.000*
Sex 
r- Value -0.008 0.223 -0.235
P - Value 0.966 0.220 0.195 
Disease Subtypes 
r- Value -0.031 0.093 -0.279
P - Value 0.866 0.614 0.122 
Disease Duration 
r- Value -0.287 -0.391 0.152 
P - Value 0.111 0.027* 0.406 
ESR 
r- Value -0.191 -2.100 0.214 
P - Value 0.296 0.248 0.241 
CRP 
r- Value -0.179 -0.072 -0.061
P - Value 0.327 0.694 0.739 
Active / Inactive disease 
(EUSTAR Score) 
r- Value 0.137 -0.042 -0.186
P - Value 0.455 0.819 0.309 
Medsger-General 
r- Value 0.114 0.121 -0.071
P - Value 0.533 0.509 0.700 
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Parameters   FMD NMD ccIMT
Medsger-Peripheral Vascular
r- Value -0.160 -0.264 0.067 
P - Value 0.381 0.144 0.715 
Medsger-Skin 
r- Value -0.385 -0.440 0.251 
P - Value 0.029* 0.012* 0.165 
Medsger-Joint / tendon 
r- Value -0.452 -0.227 0.288 
P - Value 0.009* 0.211 0.110 
Medsger-GIT 
r- Value 0.328 0.091 -0.350
P - Value 0.067 0.621 0.050 
Medsger-Lung 
r- Value 0.052 0.325 0.020 
P - Value 0.778 0.070 0.915 
The size of any correlation generally evaluates as follows: 
Value of r Qualitative Description of the Strength 
-1 Perfect negative 
(-1, -0.75) Strong negative 
(-0.75, -0.25) Moderate negative 
(-0.5, -0.25) Weak negative 
(-0.25, 0.25) No linear association 
(0.25, 0.5) Weak positive 
(0.5, 0.75) Moderate positive 
(0.75, 1) Strong positive 
1 Perfect positive 
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There was significant weak positive correlation between FMD and 
NMD. Significant moderate positive correlation was observed between 
age and ccIMT. Significant weak negative correlation was noted 
between disease duration and NMD. Significant weak negative 
correlation was seen between Medsger skin and FMD. Significant weak 
negative correlation between Medsger joint tendon and FMD non-
significant weak negative correlation between Medsger G.I.T and 
ccIMT. Non-significant weak negative correlation between Medsger 
Lung and NMD. 
CONTROLS 
There was no significant difference between patients and controls 
in BMI, BP and serum lipid profile. There was significant difference in 
FMD and ccIMT between cases and controls. FMD was significantly 
decreased in cases compared to controls. The mean FMD in cases was 
8.13% compared to 13.07% in controls. ccIMT was  significantly 
increased in cases compared to controls . The mean cc IMT in cases was 
0.67mm compared to 0.57 mm in controls. There was no significant 
difference in baseline diameter and NMD between cases and controls. 
There was significant moderate positive correlation between age and 
ccIMT. 
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CORRELATIONS BETWEEN CASES AND CONTROLS 
Parameters Cases (n=32) Controls(n=32) P - Value
Male / Female 8/32 8/32 1.000 
Mean age 36.34+10.28 36.63+10.05 0.912 
BMI (kg/m2) 20.53+1.88 20.53+2.125 1.000 
Mean duration of symptoms 3.96 - - 
Systolic BP (mmHg) 120.75+11.69 122.06+11.68 0.655 
Diastolic BP (mmHg) 82.50+5.54 81+6.12 0.308 
Total Cholesterol (mg/dl) 167.72+23.62 175.03+19.74 0.184 
Triglycerides (mg/dl) 119.16+23.29 114.34+9.89 0.336 
HDL (mg/dl) 44.06+4.23 42.41+2.49 0.061 
LDL (mg/dl) 99.78+22.01 109.44+19.16 0.066 
DIFFERENCES BETWEEN CASES AND CONTROLS 
Parameters Cases (n=32) Controls (n=32) P - Value
Baseline Diameter (mm) 3.23+0.26 3.32+0.22 0.158 
FMD (%) 8.13+2.08 13.07+2.45 0.000 
NMD (%) 19.62+3.91 19.01+3.46 0.511 
Carotid IMT (mm) 0.67+0.19 0.57+0.10 0.011 
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Parameters Cases (n=32) Controls (n=32) 
Baseline Diameter (mm) 3.23 3.32 
FMD (%) 8.13 13.07 
NMD (%) 19.62 19.01 
Carotid IMT (mm) 0.67 0.57 
3.23
8.13
19.62
0.67
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13.07
19.01
0.57
0
2
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10
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16
18
20
Cases (n=32) Controls (n=32)
Baseline Diameter (mm) FMD (%) NMD (%) Carotid IMT (mm)
 
There was no significant difference between the 2 values of 
baseline diameter, FMD,NMD and ccIMT between cases and controls 
(to assess reproducibility of our technique) 
For baseline diameter, the p value was 0.429. 
For FMD, the p value was 0.585. 
For NMD, the p value was 0.367. 
For  ccIMT, the P value was 0.809. 
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Correlations between FMD, NMD and IMT with Age (Control Groups) 
  FMD NMD ccIMT AGE 
FMD  
r-Value 1 -.167 -.107 -.170 
P- Value - .362 .559 .353 
NMD 
r-Value -.167 1 -.044 .041 
P- Value .362 - .813 .825 
ccIMT 
r-Value -.107 -.044 1 .565* 
P- Value .559 .813 - .001 
AGE 
r-Value -.170 .041 .565* 1 
P- Value .353 .825 .001 - 
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DISCUSSION 
Similar to our study, G. Szucs et al [157] observed in their 29 
SSc patients, the FMD was significantly lower (4.82 ± 3.76%) in 
comparison with the controls (8.86 ± 3.56%) (P <0.001). No difference 
was found in NMD between patients (19.13 ± 17.68%) and controls 
(13.13 ± 10.40%) (P >0.1). As against our study in which there is 
significant difference, in their study the difference was not significant 
(P=0.067)  between  increased ccIMT in SSc patients (0.67 ± 0.26mm) 
and healthy subjects (0.57 ± 0.09).Like our study, a significant  positive 
correlation between ccIMT and age in SSc (r = 0.470, P = 0.013) was 
detected, as well as in healthy controls (r = 0.61, P = 0.003), but no 
correlation was found between FMD and age ,in their study. Unlike our 
study, in which NMD displayed significant inverse correlation with the 
disease duration, in their study, ccIMT but not FMD and NMD, 
displayed significant correlation with disease duration (r = 0.472, 
P=0.011), NMD displayed significant inverse correlation with the age in 
SSc patients (r = −0.492, P = 0.012), but not in controls. In contrast to 
our study, in which there is significant positive correlation between 
FMD and NMD, they did not find any correlation between FMD, NMD, 
ccIMT and SSc subtype.  
In concurrence with our study, Bartoli.F et al [158a and b] in 
their study of 35 SSc patients and 20 healthy controls, observed FMD 
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was significantly impaired (3.41%± 4.56% versus 7.66%± 4.24%; P < 
0.037) and IMT was significantly elevated compared with healthy 
controls (0.93 ± 0.29 mm versus 0.77 ± 0.13 mm; P < 0.005). FMD was 
not significantly different in SSc with increased IMT compared with 
those with normal IMT). No correlation was found between risk factors 
for atherosclerosis and the impairment of FMD or IMT in SSc patients. 
In contrast to our study in which NMD is preserved, Rossi et al 
[159] observed flow-mediated vasodilation (FMD) and NMD were 
significantly decreased in patients with SSc (10.3 ± 8.6 versus 26.6 ± 
7.4%, P<0.001; 24.2 ± 8.4 versus 33.3 ± 10.1%, P<0.001, respectively), 
in their study of 14 SSc patients and 14 healthy controls matched for age 
and for cardiovascular risk factors. 
 After the first reports suggesting an increased prevalence of 
macrovascular involvement in SSc, several studies have been performed 
in the last decade using IMT of the carotid artery as a marker of early 
atherosclerosis. 
Lekakis et al. [160] reported impaired FMD and NMD in 12 
patients with either SSc or RP. Unfortunately, authors did not separate 
SSc from RP. Andersen et al. [24] found similar FMD and NMD in 24 
SSc patients compared with controls. However, their patient population 
also included mixed connective tissue disease (MCTD) patients. 
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Lekakis et al, [160] Kaloudi et al, [161] and Bartoli et al 
[158aandb] found strongly increased IMT values in the CCA in SSc 
patients compared with controls. 
Unlike our study, Hettema et al [162] in their study of 49 SSc 
patients, reported that  the mean IMT (median, interquartile ranges; 0.69 
mm (0.62-0.79)) was not significantly increased compared to healthy 
controls (0.68 mm (0.56-0.75, p=0.067). Also, after correction for the 
confounders age, HDL-cholesterol and LDL-cholesterol (p=0.328), no 
difference in IMT was present between SSc patients and healthy 
controls. In patients no correlations were found between maximum IMT 
and disease related variables. 
Cheng et al [163and164] found no differences in IMT values in 
SSc patients compared with controls. 
IN OUR STUDY: 
The endothelium independent vasodilatation assessed by NMD in 
SSc patients is still preserved giving an opportunity of nitroglycerine 
therapy. 
There is weak negative correlation between NMD and disease 
duration. This may be explained by the impairment of the vascular 
media late in the disease course by the pathogenic mechanisms. 
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There is no correlation between ccIMT and disease duration. This 
may be probably due to long term use of immunosuppressives in many 
patients affecting the atherogenic mechanisms favourably. 
Thus, our middle-aged SSc patients represent a population, where 
there is sub-clinical cardiovascular disease indicated by surrogate 
measures (decreased FMD and increased ccIMT) of sub-clinical 
atherosclerosis. At the same time, the preserved NMD gives us a 
possibility, to introduce nitroglycerin treatment or nitric-oxide donor 
agents in order to decrease cardiovascular risk. 
FMD using vascular ultrasonography on brachial artery represents 
a useful, noninvasive method for the assessment of endothelial 
dysfunction. Reactive hyperemia produces a shear stress stimulus that 
induces the normal endothelium to release nitric oxide (NO), which acts 
as a vasodilator. Impaired enthothelial function is associated with a 
reduced release of No and a lower vasodilation [165]. The effect of 
disease states and/ or interventions on the blood flow response to cuff 
occlusion (reactive hyperemia) is under explored. Current technology 
limits the utility of spectral Doppler to reproducibily assess changes in 
flow, which might provide useful information about endothelial function 
of the microvasculature. 
Ongoing studies in several large populations, including the 
Framingham Heart Study and the Cardiovascular Health Study , shall 
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determine whether endothelial dysfunction in the brachial artery will 
identify patients at risk for developing coronary artery disease, cerebral 
vascular disease and/ or peripheral vascular disease. The technique is 
particularly well suited for study of the earliest stages of atherosclerosis 
in children and young adults, thus providing maximal opportunity for 
prevention. 
Numerous studies have demonstrated that brachial artery 
reactivity improves with risk factor modification and treatment with 
drugs known to reduce cardiovascular risk. It remains unknown whether 
an improvement in endothelial function directly translates into improved 
outcome. In the future, however, practitioners may use brachial artery 
FMD to assess response to drug therapy and to individualize patient risk 
factor modification programs. Further studies are needed to determine 
whether the methodology is sufficiently reproducible and whether 
biological variability is sufficiently low to make assessment of FMD a 
clinically useful measure of cardiovascular risk on an individual or 
group basis. To that end, the methodology will need to mature, with 
formal opportunities for training, certification and continuing medical 
education, as currently exist for other cardiovascular testing modalities. 
FUTURE DIRECTIONS 
Commercially available technology now makes it possible to 
acquire multiple images of the brachial artery automatically using the 
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ECG signal as a trigger and to measure arterial diameter automatically 
using computer-based edge-detection techniques. This approach allows 
investigators to examine the entire time course of brachial dilation in 
response to reactive hyperemia, the true peak response, the time to peak 
and the overall duration of FMD as discussed in the previous text. The 
time course and extent of brachial expansion within a single cardiac 
cycle, possibly reflecting vessel compliance, can be examined. In the 
carotid artery, compliance has been shown to correlate with 
cardiovascular risk [166]. About 70% of the dilation observed 1 min 
after cuff release is attributable to NO synthesis. 
Further studies are needed to evaluate other vasoactive 
mechanisms and to determine whether various disease states influence 
the kinetics and/or extent of FMD. Careful examination of the 
vasodilator response to NTG provides another potential avenue for 
investigation. Although most studies have detected little effect of 
disease states on this response, there is evidence that cardiovascular risk 
factors might impair the vasodilator response to NTG, especially when a 
dose-response curve is measured. These findings are consistent with 
experimental studies demonstrating that inactivation of NO by reactive 
oxygen species is an important mechanism of vascular dysfunction. 
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 Further information about the causes of vascular dysfunction and 
the response to interventions may be gained by examining the response 
to a submaximal dose of NTG or a series of NTG doses. 
The effect of disease states and/or interventions on the blood flow 
response to cuff occlusion (reactive hyperemia) is under explored. 
Current technology limits the utility of spectral Doppler to reproducibly 
assess changes in flow, which might provide useful information about 
endothelial function of the microvasculature. 
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CONCLUSION 
1) Macrovascular involvement is also seen in SSc patients even in 
the absence of traditional cardiovascular risk factors. 
2) There is an impairment of endothelium dependent vasodilatation 
indicated by low FMD (8.13%) in SSc patients. 
3) The endothelium independent vasodilatation assessed by NMD is 
still preserved providing an opportunity of nitroglycerine therapy 
for favourably modifying the course of macrovascular pathology. 
4) Carotid atherosclerosis as measured by ccIMT is higher in SSc 
patients (0.67mm) than in controls (0.57mm). 
5) ccIMT has significant correlation (moderate positive) with age, in 
controls and in SSc patients. 
6) There is no moderate or strong correlation between FMD, NMD, 
ccIMT and SSc disease activity and clinical characteristics. 
7) FMD using vascular ultrasonography on brachial artery represents 
a simple, inexpensive, non-invasive and reproducible tool for the 
assessment of endothelial function. 
8) Future prospects of FMD technique include:  
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a. Early screening module for evaluation of endothelial 
dysfunction and to start on drugs with pleomorphic effects 
favourably modifying the clinical events like statins, ACE 
inhibitors and aspirin. 
b. Serial screening method to ascertain improvement of 
macrovascular and endothelial function while on treatment 
with immunosuppressive agents and vasodilators. 
9) The assessment of macrovascular involvement in SSc may have 
important diagnostic, prognostic and therapeutic implications in 
the management of systemic sclerosis.  
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ABBREVIATIONS 
ACR : American College of Rheumatology 
ANA : Anti Nuclear Antibody 
AVN : Avascular Necrosis 
BMI : Body Mass Index 
ccIMT : Common Carotid Intima Medial Thickness 
CHD : Coronary Heart Disease 
CRP : C-Reactive Protein 
CVD : Cardiovascular Disease 
DcSSc : Diffuse Cutaneous Systemic Sclerosis 
ECG : Electro Cardiogram 
ECHO : Echo Cardiogram 
ECM : Extra Cellular Matrix 
ELISA : Enzyme Linked Immuno Sorbent Assay 
ENA : Extractable Nuclear Antigen 
ESR : Erythrocyte Sedimentation Rate 
EUSTAR : Eular Scleroderma Trials and Research 
FMD : Flow Mediated Dilatation 
GIT : Gastrointestinal Tract 
HDL : High Density Lipoprotein 
HRCT : High Resolution Computerized Axial 
Tomography 
ILD : Interstitial Lung Disease 
LcSSc : Limited Cutaneous Systemic Sclerosis 
LDL : Low Density Lipoprotein 
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MCTD : Mixed Connective Tissue Disease 
MRSSS : Modified Rodnan Skin Scoring System 
NMD : Nitroglycerin Mediated Dilatation 
NO : Nitric Oxide 
NTG : Nitroglycerin 
SSc : Systemic Sclerosis 
UCTD : Undifferentiated Connective Tissue 
Disease 
USG : Ultrasonogram 
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CONSENT FORM 
Study Title 
EVALUATION OF MACROVASCULAR INVOLVEMENT IN 
SYSTEMIC SCLEROSIS 
 
Study Centre : Department of Rheumatology, 
 Madras Medical College, Chennai – 600 003 
 
Patient’s Name   : 
Patient’s Age   : 
Identification Number   : 
Patient may check (3 ) these boxes 
 
I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask the question and all my 
questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving any reason, without 
my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethics committee and the regulatory authorities 
will not need my permission to look at my health records both in 
respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree 
to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and to faithfully co-operate with 
the study team, and to immediately inform the study staff if I suffer 
from any deterioration in my health or well being or any unexpected 
or unusual symptoms. 
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I hereby consent to participate in this study on ‘Evaluation of 
macrovascular involvement in systemic sclerosis’. 
 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including hematological, biochemical, 
radiological and urine examination. 
 
Signature / Thumb Impression ___________________ Place _________ 
Date ____________ 
Patient’s Name and Address: __________________________________ 
Signature of the Investigator : ___________________ Place _________ 
Date ____________ 
Study Investigator’s Name : __________________________________ 
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(mm)
1 51715 33 F 2Y Lc 6.25 18.75 0.55 161 124 43 93 38 6 2 3 2 2 0 1 4 0 0 21 120 84 3.2
2 47973 28 F 5Y Lc 8.33 19.44 0.54 140 115 40 77 34 12 4 2 1 0 1 1 0 1 0 22 124 80 3.6
3 53694 19 F 2Y Lc 8.82 14.7 0.42 146 110 40 84 45 0 3 2 1 0 0 3 0 1 0 19 130 84 3.4
4 49214 36 M 8Y Lc 9.67 22.58 0.85 169 114 46 100 15 0 2 2 1 0 0 1 1 0 0 18 120 86 3.1
5 52063 30 F 1Y6M Lc 6.25 18.75 0.65 176 92 44 114 40 6 3 0 1 0 0 0 2 0 0 20 130 84 3.2
6 52169 59 F 1Y6M Lc 11.11 22.22 0.7 170 160 42 96 10 0 3 3 1 0 0 1 1 0 0 19 132 78 3.6
7 52278 25 M 1Y6M Lc 5.71 17.14 0.65 140 110 48 70 12 0 1 3 2 0 0 1 0 0 0 22 128 76 3.5
8 53218 39 F 4Y Lc 9.37 15.62 0.65 187 127 56 106 10 6 2 2 1 0 1 0 3 0 0 17 130 84 3.2
9 46208 28 F 5Y Lc 6.25 18.75 0.6 170 113 42 105 28 6 3 2 1 0 0 0 0 1 0 23 134 86 3.2
10 42652 30 F 10Y Lc 9.09 30 0.68 172 113 42 107 30 0 2 1 1 0 0 1 2 0 0 22 130 86 3
11 53065 38 F 6M Lc 9.67 19.35 0.66 118 124 40 53 45 0 3 1 1 0 1 0 1 0 0 18 120 88 3.1
12 40172 43 F 17Y Lc 5.7 14.28 0.9 180 130 42 112 114 12 3 2 2 4 0 0 0 0 1 19 122 80 3.5
13 53298 20 F 1Y Lc 8.82 17.64 0.6 187 70 42 131 10 0 1 2 1 0 0 1 0 0 0 20 130 84 3.4
14 53164 34 M 5Y Lc 12.5 21.87 0.37 180 122 41 115 20 0 2 2 1 0 0 1 1 1 0 20 106 90 3.2
15 46486 35 F 5Y Dc 6.66 20 0.7 137 108 42 73 35 0 1 3 2 0 1 0 1 0 0 19 130 84 3
16 53502 45 F 3Y Lc 6.66 16.66 0.77 181 143 50 102 50 0 2 2 1 0 0 1 1 0 0 21 126 90 3
17 53258 42 F 6M Lc 9.09 24.24 1.15 197 123 53 119 40 6 1 0 2 2 0 0 1 0 0 16 100 82 3.3
18 43105 27 F 3Y Lc 3.44 24.13 0.6 185 114 44 118 40 12 3 0 1 0 1 0 2 0 0 22 134 80 2.9
19 53195 19 F 1Y Lc 12 28 0.41 180 130 40 114 68 12 2 0 1 0 0 1 0 0 0 23 140 90 2.5
20 53230 25 F 4Y Dc 6.25 18.75 0.5 180 128 42 112 16 0 2 2 2 1 0 0 1 0 0 19 120 82 3.2
21 49206 48 M 3Y6M Lc 9.37 21.87 0.9 176 140 42 106 30 0 3 2 1 0 0 0 0 0 0 18 126 82 3.2
22 50394 46 M 3Y Dc 8.57 14.28 0.9 173 222 46 83 55 12 1 2 3 0 0 0 1 0 0 24 130 86 3.5
23 51976 60 F 1Y6M Lc 10.3 20.68 0.83 191 113 49 119 40 6 3 0 1 0 1 1 0 1 0 18 120 84 2.9
24 36349 50 F 10Y Lc 6.25 21.87 0.6 174 126 45 104 65 12 2 1 1 0 0 1 1 0 0 20 130 86 3.2
25 51884 38 F 3Y Lc 8.1 18.91 0.5 160 106 40 99 40 0 3 2 1 0 0 0 0 2 0 19 90 60 3.7
26 51286 43 M 6Y Dc 5.88 17.64 1.2 226 110 52 152 130 0 2 3 2 1 0 0 0 0 0 17 100 74 3.4
27 52909 40 F 5Y6M Lc 9.67 16.12 0.67 146 100 46 80 80 0 3 1 2 0 1 1 1 0 0 17 120 88 3.1
28 53306 32 F 8M Lc 9.37 25 0.7 188 102 42 126 55 12 2 0 1 0 1 0 4 1 0 20 110 78 3.2
29 53137 31 F 4Y Lc 9.09 18.18 0.51 177 124 44 108 120 12 2 2 1 0 0 0 1 1 0 21 120 86 3.3
30 53510 36 F 2Y Lc 7.14 21.42 0.55 118 108 46 50 28 0 1 0 2 0 0 1 2 0 0 19 130 80 2.8
31 53762 42 M 1Y Dc 5.4 13.51 0.73 146 127 41 80 71 12 1 0 2 1 0 0 0 0 1 19 100 70 3.7
32 53854 42 M 5Y Dc 9.37 15.62 0.45 136 65 38 85 30 12 1 0 2 0 0 1 0 0 0 20 110 80 3.2
S. 
NO
RCC  
NO
AGE SEX
duration  
Subtype
FMD% NMD%
ccIMT 
(mm)
T. 
cholest
TGL HDL LDL ESR CRP
M. 
Gener
M.Per. 
vas
M. 
Skin
M.Jt. 
Tend
M. 
Muscle
M.G.I.T
M. 
Lung
M. 
Heart
M. 
Kidney
BMI syst.BP diast.BP
B.dm 
(mm)
1 51715 33 F 2Y Lc 6.25 18.75 0.55 161 124 43 93 38 6 2 3 2 2 0 1 4 0 0 21 120 84 3.2
2 47973 28 F 5Y Lc 8.33 19.44 0.54 140 115 40 77 34 12 4 2 1 0 1 1 0 1 0 22 124 80 3.6
3 53694 19 F 2Y Lc 8.82 14.7 0.42 146 110 40 84 45 0 3 2 1 0 0 3 0 1 0 19 130 84 3.4
4 49214 36 M 8Y Lc 9.67 22.58 0.85 169 114 46 100 15 0 2 2 1 0 0 1 1 0 0 18 120 86 3.1
5 52063 30 F 1Y6M Lc 6.25 18.75 0.65 176 92 44 114 40 6 3 0 1 0 0 0 2 0 0 20 130 84 3.2
6 52169 59 F 1Y6M Lc 11.11 22.22 0.7 170 160 42 96 10 0 3 3 1 0 0 1 1 0 0 19 132 78 3.6
7 52278 25 M 1Y6M Lc 5.71 17.14 0.65 140 110 48 70 12 0 1 3 2 0 0 1 0 0 0 22 128 76 3.5
8 53218 39 F 4Y Lc 9.37 15.62 0.65 187 127 56 106 10 6 2 2 1 0 1 0 3 0 0 17 130 84 3.2
9 46208 28 F 5Y Lc 6.25 18.75 0.6 170 113 42 105 28 6 3 2 1 0 0 0 0 1 0 23 134 86 3.2
10 42652 30 F 10Y Lc 9.09 30 0.68 172 113 42 107 30 0 2 1 1 0 0 1 2 0 0 22 130 86 3
11 53065 38 F 6M Lc 9.67 19.35 0.66 118 124 40 53 45 0 3 1 1 0 1 0 1 0 0 18 120 88 3.1
12 40172 43 F 17Y Lc 5.7 14.28 0.9 180 130 42 112 114 12 3 2 2 4 0 0 0 0 1 19 122 80 3.5
13 53298 20 F 1Y Lc 8.82 17.64 0.6 187 70 42 131 10 0 1 2 1 0 0 1 0 0 0 20 130 84 3.4
14 53164 34 M 5Y Lc 12.5 21.87 0.37 180 122 41 115 20 0 2 2 1 0 0 1 1 1 0 20 106 90 3.2
15 46486 35 F 5Y Dc 6.66 20 0.7 137 108 42 73 35 0 1 3 2 0 1 0 1 0 0 19 130 84 3
16 53502 45 F 3Y Lc 6.66 16.66 0.77 181 143 50 102 50 0 2 2 1 0 0 1 1 0 0 21 126 90 3
17 53258 42 F 6M Lc 9.09 24.24 1.15 197 123 53 119 40 6 1 0 2 2 0 0 1 0 0 16 100 82 3.3
18 43105 27 F 3Y Lc 3.44 24.13 0.6 185 114 44 118 40 12 3 0 1 0 1 0 2 0 0 22 134 80 2.9
19 53195 19 F 1Y Lc 12 28 0.41 180 130 40 114 68 12 2 0 1 0 0 1 0 0 0 23 140 90 2.5
20 53230 25 F 4Y Dc 6.25 18.75 0.5 180 128 42 112 16 0 2 2 2 1 0 0 1 0 0 19 120 82 3.2
21 49206 48 M 3Y6M Lc 9.37 21.87 0.9 176 140 42 106 30 0 3 2 1 0 0 0 0 0 0 18 126 82 3.2
22 50394 46 M 3Y Dc 8.57 14.28 0.9 173 222 46 83 55 12 1 2 3 0 0 0 1 0 0 24 130 86 3.5
23 51976 60 F 1Y6M Lc 10.3 20.68 0.83 191 113 49 119 40 6 3 0 1 0 1 1 0 1 0 18 120 84 2.9
24 36349 50 F 10Y Lc 6.25 21.87 0.6 174 126 45 104 65 12 2 1 1 0 0 1 1 0 0 20 130 86 3.2
25 51884 38 F 3Y Lc 8.1 18.91 0.5 160 106 40 99 40 0 3 2 1 0 0 0 0 2 0 19 90 60 3.7
26 51286 43 M 6Y Dc 5.88 17.64 1.2 226 110 52 152 130 0 2 3 2 1 0 0 0 0 0 17 100 74 3.4
27 52909 40 F 5Y6M Lc 9.67 16.12 0.67 146 100 46 80 80 0 3 1 2 0 1 1 1 0 0 17 120 88 3.1
28 53306 32 F 8M Lc 9.37 25 0.7 188 102 42 126 55 12 2 0 1 0 1 0 4 1 0 20 110 78 3.2
29 53137 31 F 4Y Lc 9.09 18.18 0.51 177 124 44 108 120 12 2 2 1 0 0 0 1 1 0 21 120 86 3.3
30 53510 36 F 2Y Lc 7.14 21.42 0.55 118 108 46 50 28 0 1 0 2 0 0 1 2 0 0 19 130 80 2.8
31 53762 42 M 1Y Dc 5.4 13.51 0.73 146 127 41 80 71 12 1 0 2 1 0 0 0 0 1 19 100 70 3.7
32 53854 42 M 5Y Dc 9.37 15.62 0.45 136 65 38 85 30 12 1 0 2 0 0 1 0 0 0 20 110 80 3.2
